Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III ofatumumab vs placebo in methotrexate-inadequate response rheumatoid arthritis
2007-002950-42Phase 3Completed
- Sponsor
- Genmab
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Ofatumumab with Placebo (2 arms). Primary endpoint: ACR20 response at 24 weeks. Started Jul 2007; status: completed.
02
Drugs
ofatumumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-002950-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002950-42.